V565

V565 is a novel oral anti-tumor necrosis factor alpha (TNF-α) domain antibody engineered for the topical treatment of inflammatory bowel disease (IBD), specifically Crohn's disease. It is designed to be resistant to intestinal proteases, allowing it to survive passage through the gastrointestinal tract and act locally in the intestine. The drug is formulated as enteric-coated mini-tablets that dissolve in the jejunum and ileum, targeting inflamed areas while minimizing systemic exposure. Its mechanism of action involves inhibition of TNF-α, a key pro-inflammatory cytokine implicated in IBD pathogenesis[1][2][4].